VanEck Biotech ETF (NASDAQ:BBH) Short Interest Update

VanEck Biotech ETF (NASDAQ:BBH) saw a large growth in short interest in April. As of April 15th, there was short interest totalling 11,200 shares, a growth of 761.5% from the March 31st total of 1,300 shares. Based on an average daily trading volume, of 11,300 shares, the days-to-cover ratio is presently 1.0 days. Currently, 0.5% of the shares of the company are sold short.

Hedge Funds Weigh In On VanEck Biotech ETF

Several hedge funds have recently made changes to their positions in the stock. TD Waterhouse Canada Inc. bought a new position in shares of VanEck Biotech ETF in the fourth quarter valued at approximately $9,966,000. Bank of America Corp DE lifted its stake in VanEck Biotech ETF by 86.2% in the 4th quarter. Bank of America Corp DE now owns 86,508 shares of the company’s stock worth $13,579,000 after purchasing an additional 40,052 shares in the last quarter. Strategic Financial Concepts LLC bought a new position in VanEck Biotech ETF in the 4th quarter valued at $3,828,000. Raymond James Financial Inc. purchased a new position in shares of VanEck Biotech ETF during the 4th quarter valued at $3,381,000. Finally, Jane Street Group LLC increased its holdings in shares of VanEck Biotech ETF by 401.7% in the third quarter. Jane Street Group LLC now owns 8,348 shares of the company’s stock worth $1,481,000 after purchasing an additional 6,684 shares during the period. 32.05% of the stock is currently owned by hedge funds and other institutional investors.

VanEck Biotech ETF Trading Down 0.8 %

VanEck Biotech ETF stock opened at $149.00 on Monday. The firm has a 50 day simple moving average of $156.03 and a 200 day simple moving average of $161.87. VanEck Biotech ETF has a 1-year low of $135.34 and a 1-year high of $183.64. The firm has a market capitalization of $341.21 million, a price-to-earnings ratio of 31.41 and a beta of 0.82.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.